Free Articles, Free Web Content, Reprint Articles
Tuesday, May 21, 2019
 
Free Articles, Free Web Content, Reprint ArticlesRegisterAll CategoriesTop AuthorsSubmit Article (Article Submission)ContactSubscribe Free Articles, Free Web Content, Reprint Articles
 

Antisense and RNAi Therapeutic Market to 2022 – Market Estimate, Industry Size: Grand View Research,

New Market Research Reports Title “Antisense and RNAi Therapeutic Market Analysis Size and Segment Forecasts to 2022” Has Been Added to GrandViewResearch.com Report Database

Global antisense & RNAi therapeutic market is expected to witness a lucrative growth rate during the forecast period owing to rising prevalence of infectious diseases, and coronary heart disorders which lead to cardiovascular diseases. Incorporation of technologically advanced RNA based technologies such as RNA antisense; RNA nanobiotechnologies, RNA interference, and SMaRT technology are also expected to drive market demand. Furthermore, growing needs for high throughput therapeutic tools for treatment of neurometabolic disorders such as amyotrophic lateral sclerosis, Huntington’s disease and Alzheimer’s disease, and rising awareness regarding tissue specificity for drug delivery about RNA based drugs are factors expected to fuel the growth for gene synthesizing mechanisms & cellular gene silencing. However, huge investment requirement in drug delivery & research and high treatment success rates are some factors that are expected to boost market growth.

Browse full research report on Global Antisense and RNAi Therapeutic Market: http://www.grandviewresearch.com/industry-analysis/global-antisense-and-rni-therapeutic-market

Increasing awareness towards the use of aptamers and ribozymes for suppression of target genes, and there selective expression in order to treat diseases at a genomic level prior to protein expression is also expected to promote the market growth. Increasing usage of RNAi technology based therapeutics for infectious diseases such as HIV, viral hepatitis and cancer in order to overcome the adverse effects observed by consumption of generic drugs and inhibit the metabolic growth of causative micro-organism are expected to drive demand for antisense & RNAi therapeutic market through to 2022. Furthermore, approval of different novel drugs for the treatment of cholesterol associated disorders and ocular diseases are anticipated to have a positive impact on the growth of this market in the coming seven years.

Request For TOC of this report: http://www.grandviewresearch.com/industry-analysis/global-antisense-and-rni-therapeutic-market/request-toc

The geographical analysis of antisense & RNAi therapeutic market divides it into Europe, North America, Asia-Pacific, Latin America and MEA. North America held the largest share in market revenue in 2014 as a consequence of rise in incidence of cardiovascular, genetic and neurometabolic disorders. Other factors contributing towards large market share of the region include rise in number of R&D institutes and laboratories involved in development of bioinformatics based research for disease prognosis. However, Asia Pacific region with emerging economies such as India and China is expected to grow at a significantly faster rate in the RNAi and antisense therapeutic market. Factors attributing this anticipated growth of this region include presence of unmet market demand, and increased used of miRNA as a disease marker for oncology diseases. Furthermore, presence of many antisense and siRNA molecules in the pipeline for drug development under clinical trials for regulatory approval is expected to fuel the market growth during the forecast period.

 Access More reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/biotechnology

Key participants in the market include Sanofi, Allergan, Benitec Biopharma, Biogen, Atlantic Pharmaceuticals, Inc., Enzon Pharmaceuticals Inc., AstraZeneca, Bristol-Myers Squibb, Acuitas Therapeutics, Glaxosmithkline, Isis Pharmaceuticals, Dicerna Pharmaceuticals, Antisense Therapeutics, Dainippon Sumitomo Pharma, Roche Holding AG and Tekmira Pharmaceuticals. Competitive strategies adopted by the market players include collaborations for development and commercialization of antisense and RNAi drugs in the pharmaceutical and biotechnological market.

 For more informationArticle Submission, visit: http://www.grandviewresearch.com/

                                                                                                                                                    

Source: Free Articles from ArticlesFactory.com

ABOUT THE AUTHOR


Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights.

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Read our blogs - www.divog.org, www.legalworkshop.org, www.qyresearchreports.biz



Health
Business
Finance
Travel
Technology
Home Repair
Computers
Marketing
Autos
Family
Entertainment
Law
Education
Communication
Other
Sports
ECommerce
Home Business
Self Help
Internet
Partners


Page loaded in 0.221 seconds